UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies

British journal of cancer, 2004-03, Vol.90 (6), p.1133-1137

2004

Volltextzugriff (PDF)

The AST/ALT (De Ritis) ratio predicts clinical outcome in pancreatic cancer patients treated with first-line nab-paclitaxel and gemcitabine: post-hoc analysis of an Austrian multicenter, non-interventional study

Annals of oncology, 2019-07, Vol.30, p.iv78-iv78

2019

Volltextzugriff (PDF)

Austrian real world data in elderly and younger metastatic pancreatic cancer patients: Interim results of a multicenter non-interventional study with nab-paclitaxel/gemcitabine

Annals of oncology, 2018-06, Vol.29, p.v9-v10

2018

Volltextzugriff (PDF)

Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate

Supportive care in cancer, 2003-08, Vol.11 (8), p.539-547

2003

Volltextzugriff (PDF)

Renal safety profiles of ibandronate 6 mg infused over 15 and 60 min: a randomized, open-label study

Annals of oncology, 2008-07, Vol.19 (7), p.1266-1270

2008

Volltextzugriff (PDF)

Myeloma Bone Disease: Update on Pathogenesis and Novel Treatment Strategies

Pharmaceutics, 2018-10, Vol.10 (4), p.202

2018

Volltextzugriff (PDF)

Rapid administration of ibandronate does not affect renal functioning: evidence from clinical studies in metastatic bone disease and hypercalcaemia of malignancy

Supportive care in cancer, 2004-12, Vol.12 (12), p.877-881

2004

Volltextzugriff (PDF)

Biochemical Markers of Bone Formation in Patients with Plasma Cell Dyscrasias and Benign Osteoporosis

Clinical chemistry (Baltimore, Md.), 2001-04, Vol.47 (4), p.686-693

2001

Volltextzugriff (PDF)

Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy

Journal of clinical oncology, 1996-01, Vol.14 (1), p.268-276

1996

Volltextzugriff (PDF)

Renal safety profile of ibandronate 6mg infused over 15 or 60 min in breast cancer patients with bone metastases

Bone (New York, N.Y.), 2008-03, Vol.42, p.S107-S107

2008

Volltextzugriff (PDF)

Managing neoplastic bone disease with ibandronic acid: a preclinical and clinical data update

Expert opinion on pharmacotherapy, 2008-12, Vol.9 (17), p.3111-3119

Pecherstorfer, Martin

2008

Volltextzugriff (PDF)

Interleukin-6 and tumor necrosis factor α levels after bisphosphonates treatment in vitro and in patients with malignancy

Bone (New York, N.Y.), 1996-02, Vol.18 (2), p.133-139

1996

Volltextzugriff (PDF)

Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma

British journal of cancer, 2001-02, Vol.84 (3), p.344-351

2001

Volltextzugriff (PDF)

Parathyroid hormone-related protein and life expectancy in hypercalcemic cancer patients

The journal of clinical endocrinology and metabolism, 1994-05, Vol.78 (5), p.1268-1270

1994

Volltextzugriff (PDF)

Serum Parathyroid Hormone-Related Protein Levels and Response to Bisphosphonate Treatment in Hypercalcemia of Malignancy

The journal of clinical endocrinology and metabolism, 1999-10, Vol.84 (10), p.3545-3550

1999

Volltextzugriff (PDF)

Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer

Pain (Amsterdam), 2004-10, Vol.111 (3), p.306-312

2004

Volltextzugriff (PDF)

P-286The AST/ALT (De Ritis) ratio predicts clinical outcome in pancreatic cancer patients treated with first-line nab-paclitaxel and gemcitabine: post-hoc analysis of an Austrian multicenter, non-interventional study

Annals of oncology, 2019-07, Vol.30 (Supplement_4)

2019

Volltextzugriff (PDF)

Cutaneous Melanoma Metastases

The New England journal of medicine, 1997-11, Vol.337 (20), p.1435-1435

Pecherstorfer, Martin

1997

Volltextzugriff (PDF)

Pathophysiology, risk factors and management of bisphosphonate-associated osteonecrosis of the jaw: Is there a diverse relationship of amino- and non-aminobisphosphonates?

Critical reviews in oncology/hematology, 2007-12, Vol.64 (3), p.198-207

2007

Volltextzugriff (PDF)

P-034Austrian real world data in elderly and younger metastatic pancreatic cancer patients: Interim results of a multicenter non-interventional study with nab-paclitaxel/gemcitabine

Annals of oncology, 2018-06, Vol.29 (suppl_5)

2018

Volltextzugriff (PDF)

Secondary resectability rates observed in a multicenter randomized phase II study of modified capecitabine/irinotecan (mXELIRI) plus bevacizumab (bev) followed by capecitabine/oxaliplatin (XELOX) plus bev or the reverse sequence in patients with metastatic colorectal cancer (mCRC)

Annals of oncology, 2016-10, Vol.27, p.vi162-vi162

2016

Volltextzugriff (PDF)

Efficacy and safety of ibandronate in the treatment of neoplastic bone disease

Expert opinion on pharmacotherapy, 2004-11, Vol.5 (11), p.2341-2350

Pecherstorfer, Martin

2004

Volltextzugriff (PDF)

The diagnostic value of urinary pyridinium cross-links of collagen, serum total alkaline phosphatase, and urinary calcium excretion in neoplastic bone disease

The journal of clinical endocrinology and metabolism, 1995, Vol.80 (1), p.97-103

1995

Volltextzugriff (PDF)

Comparative tolerability of drug therapies for hypercalcaemia of malignancy

Drug safety, 1999-11, Vol.21 (5), p.389-406

1999

Volltextzugriff (PDF)

Regional Cerebral Blood Flow in Patients Suffering from Post-Traumatic Stress Disorder

Neuropsychobiology, 2001-01, Vol.43 (4), p.260-264

2001

Volltextzugriff (PDF)

1 – 25 von 140

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(121)
Mit Volltextzugriff
(82)

Publikationsform

Artikel
(139)
Tagungsberichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies

The AST/ALT (De Ritis) ratio predicts clinical outcome in pancreatic cancer patients treated with first-line nab-paclitaxel and gemcitabine: post-hoc analysis of an Austrian multicenter, non-interventional study

Austrian real world data in elderly and younger metastatic pancreatic cancer patients: Interim results of a multicenter non-interventional study with nab-paclitaxel/gemcitabine

Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate

Renal safety profiles of ibandronate 6 mg infused over 15 and 60 min: a randomized, open-label study

Myeloma Bone Disease: Update on Pathogenesis and Novel Treatment Strategies

Rapid administration of ibandronate does not affect renal functioning: evidence from clinical studies in metastatic bone disease and hypercalcaemia of malignancy

Biochemical Markers of Bone Formation in Patients with Plasma Cell Dyscrasias and Benign Osteoporosis

Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy

Renal safety profile of ibandronate 6mg infused over 15 or 60 min in breast cancer patients with bone metastases

Managing neoplastic bone disease with ibandronic acid: a preclinical and clinical data update

Interleukin-6 and tumor necrosis factor α levels after bisphosphonates treatment in vitro and in patients with malignancy

Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma

Parathyroid hormone-related protein and life expectancy in hypercalcemic cancer patients

Serum Parathyroid Hormone-Related Protein Levels and Response to Bisphosphonate Treatment in Hypercalcemia of Malignancy

Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer

P-286The AST/ALT (De Ritis) ratio predicts clinical outcome in pancreatic cancer patients treated with first-line nab-paclitaxel and gemcitabine: post-hoc analysis of an Austrian multicenter, non-interventional study

Cutaneous Melanoma Metastases

Pathophysiology, risk factors and management of bisphosphonate-associated osteonecrosis of the jaw: Is there a diverse relationship of amino- and non-aminobisphosphonates?

P-034Austrian real world data in elderly and younger metastatic pancreatic cancer patients: Interim results of a multicenter non-interventional study with nab-paclitaxel/gemcitabine

Secondary resectability rates observed in a multicenter randomized phase II study of modified capecitabine/irinotecan (mXELIRI) plus bevacizumab (bev) followed by capecitabine/oxaliplatin (XELOX) plus bev or the reverse sequence in patients with metastatic colorectal cancer (mCRC)

Efficacy and safety of ibandronate in the treatment of neoplastic bone disease

The diagnostic value of urinary pyridinium cross-links of collagen, serum total alkaline phosphatase, and urinary calcium excretion in neoplastic bone disease

Comparative tolerability of drug therapies for hypercalcaemia of malignancy

Regional Cerebral Blood Flow in Patients Suffering from Post-Traumatic Stress Disorder

Suchergebnisse filtern